As an early funder of Entrada Therapeutics, CureDuchenne is pleased to share that after the independent Data Monitoring Committee reviewed the safety data from Cohort 1 of the ELEVATE-44-201 trial in individuals with Duchenne amenable to skipping exon 44, Entrada received recommendation to initiate the higher dose Cohort 2 at 12 mg/kg. Entrada expects to report data from Cohort 1, which was dosed at 6 mg/kg, in Q2 2026, and data from Cohort 2 by the end of the year.
Link to news release: https://ir.entradatx.com/news-releases/news-release-details/independent-data-monitoring-committee-recommends-initiation
Community letter: https://mailchi.mp/entradatx/entrada-february-17-community-update
The post Entrada to initiate an increased dose cohort in their Duchenne exon-44 skipping program appeared first on CureDuchenne.